Open AccessProlonged overall survival of patients with leptomeningeal carcinomatosis from nonsmall cell lung cancer
Author(s) -
Yanfang Ju,
Shengjie Sun,
Jinliang Wang,
Shunchang Jiao
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.191638
Subject(s) - medicine , nimotuzumab , intrathecal , lung cancer , oncology , cerebrospinal fluid , meningeal carcinomatosis , lung , cancer , gastroenterology , surgery , epidermal growth factor receptor
Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy. Nimotuzumab was well tolerated used in intrathecal therapy.